Advertisement

Topics

Uncertainty Over Safety May Affect Approval of Janssen Drug

07:15 EDT 3 Aug 2017 | PharmPro

FDA advisory committee does not recommend approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. The committee expressed concern over uncertainty regarding its safety profile.
Contributed Author: 
Janssen Biotech, Inc.
Topics: 

Original Article: Uncertainty Over Safety May Affect Approval of Janssen Drug

NEXT ARTICLE

More From BioPortfolio on "Uncertainty Over Safety May Affect Approval of Janssen Drug"

Quick Search
Advertisement
 

Relevant Topics

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...